Urovant hops across the pond, out-licensing overactive bladder drug to Pierre Fabre for $75M

Paul Schloesser

Associate Editor

Urovant Sciences, the former subsidiary of Vivek Ramaswamy’s Roivant Sciences, is branching out across the Atlantic in a new licensing deal.

The California biotech and French multinational pharma and cosmetics company Pierre Fabre jointly announced Tuesday that they are pairing up, with Urovant giving Pierre Fabre the rights to register and commercialize overactive bladder drug vibegron, known as Gemtesa in several markets, including the entire EU, Iceland, Liechtenstein, Norway, the UK and Switzerland. The deal also includes a few option territories which, according to a statement, include “French-speaking countries of Sub-Saharan Africa, Turkey and certain Eastern European countries.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Urovant hops across the pond, out-licensing overactive bladder drug to Pierre Fabre for $75M

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force

Urovant hops across the pond, out-li­cens­ing over­ac­tive blad­der drug to Pierre Fab­re for $75M

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Urovant hops across the pond, out-licensing overactive bladder drug to Pierre Fabre for $75M

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force